In reviewed upper-endoscopy cohorts, pooled GLP-1 drugs including liraglutide were associated with higher gastric residual content rates than non-use (OR 5.57, 95% CI 4.07 to 7.62); no native-specific estimate was supplied.
In plain wordsIn endoscopy cohorts, pooled drugs including liraglutide were linked to higher retained-content rates than non-use.
- Peptide
- Liraglutide
- Outcome
- IncreaseGastric residual content
- Study
n: not reported in source
- Comparator
- Non-users
- Analysis
- Primary
- Outcome group
- Gastrointestinal adverse events · Gastrointestinal
Measurements
- Odds ratio
- 5.57
- gastric residual content
- 95% CI
- 4.07 to 7.62
- gastric residual content
Source sentences
GLP-1 RA use demonstrated significantly higher rates of GRC compared to non-users (OR: 5.57; 95% CI: 4.07-7.62), an association that remained statistically significant on the analysis of adjusted ORs (3.18; 95% CI: 2.75-3.67).
4 context sentences(design, population, supporting numbers)
We conducted a systematic review of studies from PubMed, Embase, and Cochrane databases (until November 2024), as well as relevant abstracts from Digestive Disease Week (DDW) 2024 and American College of Gastroenterology (ACG) 2024 to assess the impact of GLP-1 receptor agonists (GLP-1 RAs) on EGD.
The primary analysis assessing the association between GLP-1 RA use and GRC or aspiration events included 20 retrospective studies with a total of 207,708 patients (23,366 GLP-1 RA users).
A network meta-analysis comparing semaglutide (PO/SQ), exenatide, liraglutide and dulaglutide in terms of GRC showed no significant difference across these agents (chi square 0.966, p = 0.96).
The primary outcomes were the rate of GRC and the rate of aspiration pneumonia.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.